Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Boutouyrie

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|April 22, 2010
Arguments against precompetitive collaborationG Vargas, B Boutouyrie, S Ostrowitzki, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Critical limits to define a lab adverse event during phase I studies: a study in 1134 subjectsM Sibille, V Bresson, A Janin, et al.
European Journal of Clinical Pharmacology|January 1, 1995
Upper limit of plasma alanine amino transferase during phase I studiesM Sibille, L G Lassonery, A Janin, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|April 22, 2010
Arguments against precompetitive collaborationG Vargas, B Boutouyrie, S Ostrowitzki, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Critical limits to define a lab adverse event during phase I studies: a study in 1134 subjectsM Sibille, V Bresson, A Janin, et al.
European Journal of Clinical Pharmacology|January 1, 1995
Upper limit of plasma alanine amino transferase during phase I studiesM Sibille, L G Lassonery, A Janin, et al.
Pageof 1